Ghana has rejected a bilateral health deal with the U.S., a source ‌familiar with the negotiations told Reuters, the latest stumbling block to the Trump administration’s effort to overhaul foreign aid.

The government of President John Dramani Mahama has hesitated at terms requiring the sharing of sensitive health data, the source said.

Spokespersons for Ghana’s foreign ministry and government have not responded to requests for comment. However, The U.S. ​State Department also has said that it does not disclose details of bilateral negotiations.

“We continue to look for ways to strengthen the bilateral partnership between our two countries,” a spokesperson said.

The Trump administration in September announced a new “America First Global Health Strategy” that calls for poorer nations to play a bigger role in fighting HIV/AIDS, malaria, tuberculosis and polio in their countries and eventually transition from aid to self-reliance. However, The U.S. Agency for International Development was dismantled last year.

The source also has disclosed that there is intense pressure from the U.S. side to sign the deal.

The U.S. has disbursed $219 million (USD) in foreign assistance to ‌Ghana, ⁠including $96 million specifically for health, for 2024, the year before the Trump administration’s cuts to foreign aid, according to government foreign assistance data. This deal that the two sides started negotiating last November would have called for $109 million (USD) in U.S. assistance for health over five years, the source said. It was unclear how much Ghana would have been expected ⁠to pay.

“They were pretty normal dealings and negotiations in the beginning, and then increasingly there was a lot more pressure, especially at the end,” the source said.

Washington then set April 24 as the deadline to conclude the negotiations, and ⁠Accra decided it could not agree to what was being proposed, the source said.

Ghana has communicated its position to the Trump administration, the source said.

Additional Sources: Reuters

LEAVE A REPLY

Please enter your comment!
Please enter your name here